Colon carcinoma is one of the most commonly occurring cancer type around the globe, it is usually developed in parts of the large intestine such as colon or rectum. The underlining cause of the cancer is an abnormal growth of cells in the parts of the large intestine due to certain cellular mutation. These cancer cells often lead to the growth of tumor in the respective area and are capable of invading other parts of the body. People over the age of 50 are more prone to the disease as incidence ratio is high amongst the geriatric population. Higher consumption of junked food, red meat and processed meat and lack of physical activity are linked with colon carcinoma. Health experts also suggest obesity, excessive smoking and consumption of alcohol as other factors that may cause the disease.
Few of the symptoms include blood in the stool, abnormal bowel movements, constipation weakness, vomiting, weight loss and nausea. At times, colon carcinoma may also root other complications such as inflammatory bowel disorders.
Higher emphasis on further development of anti-carcinogenic drugs is expected to deliver some promising outcomes in the near future. Currently, colon carcinoma has four common treatment modules namely chemotherapy, immunotherapy, targeted therapy and laparoscopic surgery. In the recent years, laparoscopic surgery has become more popular as the treatment is less painful delivering greater results.
Download free exclusive Brochure of this report:
Increasing Incidence Rate and Higher Demand of Cancer Therapeutics is expected to drive the Global Colon Carcinoma Therapeutics Market
Increasing geriatric population and changing lifestyle are the major cause of the disease. Being one of the most commonly occurring cancers, the demand for its treatment is growing at a significant rate. Further, increasing awareness and early diagnosis are expected to fuel the global colon carcinoma therapeutics market in the near future. The demand for anti-carcinogenic drugs and therapies in many of the Asian countries is growing at a healthy pace and is expected to favor the overall market. With each coming year, the number of incidences is increasing and is considered as a major factor driving the global market.
On the other hand, despite increasing research and medicinal advancements, a complete cure for the disease is still not available. Biomedical researchers, scientist and health experts have seen success in extending the life expectancy of the patients, however, mortality rate still remains high in most cases. Other factors curtailing the growth of the market include high-cost of treatment, adverse side effects and credibility of drugs. Apart from these, long durations of research and heavy financial investments required for conducting preclinical research and development programs are major concerns for the pharmaceutical companies supplying colon carcinoma drugs.
Most patients receiving cancer treatments are subjected to severe side effects such as weight loss, hair loss and extreme weakness. Hence, drug manufacturers are highly focusing on enhancing the conventional methods of treatment. Over the past few years, a range of novel anti-carcinogenic drugs has introduced in the market by different brands. Furthermore, advanced screening test and surgery techniques such as robotic surgery has come up and are considered beneficial for the global colon carcinoma therapeutics market in the coming years.
Browse exclusive Global strategic Business report:
Colon Carcinoma Therapeutics Market: Regional Segmentation
On the basis of region, the global colon carcinoma therapeutics market has been segmented into six key regions namely North America, Western Europe, Eastern Europe, Latin America, Asia Pacific (APAC), and the Middle East & Africa (MEA). North America is considered one of the largest markets of colon carcinoma therapeutics. In addition, the U.S. accounted for more than one million new cases of colon carcinoma in 2015 and the number is expected to increase with each coming year.
Few of the key players identified in the global colon carcinoma therapeutics market include Novartis International AG, F. Hoffmann-La Roche AG, AMGen, Celgene Corporation, Bristol-Myers Squibb, Merck & Co., Inc.